Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Med Pediatr Oncol ; 36(1): 190-3, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11464880

ABSTRACT

BACKGROUND: Angiogenesis plays a crucial role in the progression and metastasis of malignant solid tumors. In many types of cancer, including neuroblastoma, high tumor vascularity correlates with poor outcome. Recently, a number of angiogenic inhibitors have been identified that had antitumor activity in preclinical studies. PROCEDURE: To investigate the effect of the antiangiogenic agent TNP-470 on neuroblastoma tumor growth, we treated nude mice with TNP-470 after they were inoculated subcutaneously with 5 x 10(6) cells from the MYCN-amplified, human neuroblastoma cell line NBL-W-N. RESULTS: TNP-470 did not significantly affect tumor growth when it was administered to mice with large tumors (>600 mm3). However, when TNP-470 was administered in the setting of microscopic disease 12 hr following tumor cell inoculation, treated mice had a significantly improved tumor-free survival at 12 weeks (P < 0.001), and overall survival at 45 weeks (P < 0.001), compared to control animals. CONCLUSIONS: Our studies suggest that TNP-470 treatment may be most effective if it is administered in the setting of microscopic disease. We speculate that TNP-470 may inhibit neuroblastoma growth in children if treatment is initiated following intensive multimodality therapy, when residual disease is minimal.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Neovascularization, Pathologic/drug therapy , Neuroblastoma/drug therapy , Sesquiterpenes/therapeutic use , Animals , Cell Division , Cyclohexanes , Humans , Male , Mice , Mice, Nude , Neuroblastoma/blood supply , Neuroblastoma/pathology , O-(Chloroacetylcarbamoyl)fumagillol , Tumor Cells, Cultured/transplantation , Xenograft Model Antitumor Assays
2.
J Clin Oncol ; 19(4): 1047-55, 2001 Feb 15.
Article in English | MEDLINE | ID: mdl-11181668

ABSTRACT

PURPOSE: To investigate whether the rate of neurologic recovery or the incidence of long-term sequelae differed for children with neuroblastoma (NB) initially treated with chemotherapy versus surgical decompression with laminectomy, we reviewed the Pediatric Oncology Group (POG) experience. PATIENTS AND METHODS: A retrospective review of children diagnosed with intraspinal NB registered on POG NB Biology Protocol 9047 was performed. Survival, neurologic outcome, and orthopedic sequelae were evaluated according to age of the patient at diagnosis, stage of disease, duration and severity of neurologic symptoms, and therapeutic intervention. RESULTS: Between May 1990 and January 1998, 83 children with intraspinal NB were entered onto the study. Five-year survival for this cohort of patients was 71% +/- 9%. Forty-three (52%) of the patients had neurologic symptoms at diagnosis. After treatment, six of 15 severely affected patients, who presented with paralysis, completely recovered neurologic function. Two of five patients with moderate deficits, consisting of paresis and bowel/bladder dysfunction, completely recovered neurologic function. Seventeen of 22 assessable children, who had mild symptoms comprised of paresis alone, fully recovered. Seven of 24 assessable patients who had undergone laminectomy developed scoliosis, whereas spinal deformities were only detected in one of 49 assessable patients managed without laminectomy (P =.001). CONCLUSION: The frequency of complete neurologic recovery in children with intraspinal NB inversely correlated with the severity of the presenting neurologic deficits. The rate of neurologic recovery was similar for patients treated with chemotherapy compared to those managed with laminectomy. Fewer orthopedic sequelae were observed in the children managed with chemotherapy than were seen in children managed with laminectomy.


Subject(s)
Neuroblastoma/therapy , Spinal Neoplasms/therapy , Adolescent , Child , Child, Preschool , Humans , Infant , Infant, Newborn , Laminectomy , Neuroblastoma/physiopathology , Paresis/therapy , Peripheral Nervous System Diseases/etiology , Retrospective Studies , Spinal Neoplasms/physiopathology , Treatment Outcome
3.
J Clin Oncol ; 18(21): 3604-13, 2000 Nov 01.
Article in English | MEDLINE | ID: mdl-11054433

ABSTRACT

PURPOSE: The clinical significance of MYCN expression in children with neuroblastoma (NB) remains controversial. To determine the prognostic significance of MYCN expression in the absence of MYCN amplification, we analyzed MYCN mRNA and protein expression in tumors from 69 patients. PATIENTS AND METHODS: Sixty-nine NB tumor samples with nonamplified MYCN from patients with stage C or D disease were obtained from the Pediatric Oncology Group Neuroblastoma Tumor Bank. MYCN mRNA was analyzed using a real-time reverse transcriptase polymerase chain reaction assay, and MYCN protein was examined by Western blot analyses. RESULTS: The estimated 5-year event-free survival (EFS) and survival (S) rates plus SE for the cohort were 57% +/- 17% and 60% +/- 16%, respectively. Infants younger than 1 year had significantly higher rates of EFS and S than children >/= 1 year of age (P =.003 and P <.001, respectively); patients with stage C disease had better outcome than those with stage D NB (P <.001); and patients with hyperdiploid tumors had better outcome than those with diploid NB (P <.001). Surprisingly, outcome was slightly better for patients with high versus low levels of MYCN mRNA expression (4-year S, 70% +/- 13% v 50% +/- 16%; P =.290), and for patients with tumors that expressed MYCN protein (4-year S, 73% +/- 19% v 53% +/- 15%, respectively; P =.171). CONCLUSION: High levels of MYCN expression are not prognostic of adverse outcome in patients with advanced-stage NB with nonamplified MYCN. A trend associating high levels of MYCN expression with improved outcome was observed.


Subject(s)
Genes, myc/genetics , Neuroblastoma/genetics , Blotting, Western , Cohort Studies , Female , Gene Amplification , Gene Expression , Humans , Infant , Male , Neoplasm Staging , Neuroblastoma/metabolism , Neuroblastoma/pathology , Prognosis , Proto-Oncogene Proteins c-myc/biosynthesis , Proto-Oncogene Proteins c-myc/genetics , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Reproducibility of Results , Reverse Transcriptase Polymerase Chain Reaction , Survival Analysis
4.
J Clin Oncol ; 18(14): 2789-91, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10894881
5.
Clin Cancer Res ; 5(12): 4273-8, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10632370

ABSTRACT

Angiogenesis plays an important role in the growth and metastasis of malignant tumors. We have previously reported that in children with neuroblastoma (NB), tumor vascularity directly correlates with metastatic disease, MYCN amplification, and poor outcome. The angiogenesis inhibitor TNP-470 has been shown to reduce the rate of NB growth in rodents with macroscopic tumors without ultimately impacting survival. To investigate whether TNP-470 could more effectively inhibit NB growth in animals with a low tumor burden, we treated 30 nude mice with minimal disease with this angiogenesis inhibitor (supplied by TAP Pharmaceuticals, Inc.). Therapy was initiated before tumors were clinically evident after s.c. inoculation of 5 x 10(6) cells from the MYCN-amplified NB cell line NBL-W-N. TNP-470 was administered 3 days/week, and after 12 weeks of treatment, 53% of the treated mice remained tumor free, whereas 100% of the control mice developed tumors (P < 0.0001). To further assess the relationship between the efficacy of TNP-470 treatment and tumor burden, TNP-470 was also administered s.c., 3 days/week, to mice with clinically evident small (<400 mm3; n = 15) and large (>400 mm3; n = 11) tumors. For animals with small tumors, the mean rate of growth was significantly decreased in the treated mice compared to the controls (P = 0.02). In contrast, there was no difference in the mean rate of tumor growth between animals with large tumors treated with TNP-470 and controls (P = 0.64). Our studies demonstrate that the effectiveness of TNP-470 inversely correlates with tumor burden. We speculate that TNP-470 may most effectively inhibit NB tumor growth in children with a low tumor burden.


Subject(s)
Angiogenesis Inhibitors/pharmacology , Antibiotics, Antineoplastic/pharmacology , Growth Inhibitors/pharmacology , Neuroblastoma/pathology , Sesquiterpenes/pharmacology , Animals , Cell Division/drug effects , Cyclohexanes , Humans , Male , Mice , Mice, Nude , Neoplasm Staging , Neoplasm Transplantation , Neovascularization, Pathologic , Neuroblastoma/blood supply , Neuroblastoma/drug therapy , O-(Chloroacetylcarbamoyl)fumagillol , Transplantation, Heterologous , Tumor Cells, Cultured
6.
J Clin Oncol ; 16(6): 2007-17, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9626197

ABSTRACT

PURPOSE: Although a high rate of spontaneous regression is observed in infants with stage D(S) neuroblastoma (NB), survival is not uniform. To determine the prognostic relevance of age at diagnosis, therapy, and tumor biology in infants with stage D(S) NB, we reviewed the Pediatric Oncology Group (POG) experience. PATIENTS AND METHODS: A review of patients diagnosed with stage D(S) NB registered on POG protocols was performed. Survival according to age at diagnosis, treatment, and tumor biology was determined. RESULTS: Between 1987 and 1996, 110 infants with stage D(S) NB had an estimated 3-year survival rate of 85% +/- 4%; survival rate was 71% +/- 8% for infants 2 months of age or younger, and 68% +/- 12%, 44% +/- 33%, and 33% +/- 19% for patients with diploid, MYCN-amplified, and unfavorable histology tumors, respectively. Survival rates were similar for patients who received adjuvant chemotherapy versus those who did not (82% +/- 5% v 93% +/- 6%, respectively; P = .187). Furthermore, there was no statistical difference in survival rate for patients who underwent complete resection of their primary tumor compared with those who underwent partial resection or biopsy only (90% +/- 5% v 78% +/- 7%, respectively; P = .083). CONCLUSION: Our review confirmed that the survival of infants with stage D(S) NB is excellent. However, subsets of patients with poor prognosis can be identified by young age and unfavorable biologic factors. More effective therapy is needed for the group of stage D(S) infants who show unfavorable clinical and biologic features.


Subject(s)
Neuroblastoma/diagnosis , Neuroblastoma/genetics , Age Factors , Diploidy , Female , Humans , Infant , Infant, Newborn , Male , Neuroblastoma/mortality , Neuroblastoma/pathology , Neuroblastoma/therapy , Prognosis , Proto-Oncogene Proteins c-myc/genetics , Retrospective Studies , Survival Rate
7.
Curr Opin Oncol ; 10(1): 43-51, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9466484

ABSTRACT

Neuroblastoma, a childhood neoplasm arising from neural crest cells, is characterized by a diversity of clinical behavior, ranging from spontaneous remission to rapid tumor progression and death. To some extent, outcome can be predicted by the stage of disease and age at diagnosis. The molecular events responsible for the variability in response to treatment and rate of tumor growth, however, remain largely unknown. Over the past decade, transformation-linked genetic changes have been identified in neuroblastoma tumors that have contributed to our understanding of tumor predisposition, metastasis, treatment responsiveness, and prognosis. This review discusses the recent advances in the understanding of neuroblastoma at the cellular and molecular levels, and the role that tumor biology plays in determining appropriate risk-based treatment for patients with neuroblastoma.


Subject(s)
Brain Neoplasms , Neuroblastoma , Animals , Brain Neoplasms/diagnosis , Brain Neoplasms/etiology , Brain Neoplasms/therapy , Child , Child, Preschool , Humans , Infant , Infant, Newborn , Neuroblastoma/diagnosis , Neuroblastoma/etiology , Neuroblastoma/therapy , Prognosis
8.
Bone Marrow Transplant ; 20(7): 543-51, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9337055

ABSTRACT

A single institutional pilot study was conducted in which 12 poor-risk neuroblastoma (NB) patients were uniformly treated with multi-agent induction chemotherapy followed by myeloablative consolidation chemotherapy and unpurged peripheral blood stem cell (PBSC) rescue. In addition to using standard criteria for evaluating response to induction chemotherapy, tumor cell contamination of the peripheral blood and/or bone marrow was analyzed in seven patients by immunocytology using a panel of five anti-NB monoclonal antibodies. Seven patients had morphologic evidence of bone marrow disease at the time of diagnosis, and two additional patients had tumor cells detected in bone marrow samples by immunocytology prior to the second cycle of chemotherapy. After three cycles of chemotherapy, two of the 12 patients continued to have evidence of bone marrow disease. Samples from 29 PBSC harvests collected from nine patients were also analyzed for the presence of contaminating tumor cells by immunocytology. In each case, the stem cells were found to be free of tumor. Eleven of the 12 patients underwent myeloablative therapy and PBSC rescue; five patients remain alive without disease progression, 28+ to 53+ months from diagnosis, and six patients have developed recurrent disease. We conclude that PBSCs can be successfully harvested from children with NB, and used for hematopoietic reconstitution following myeloablative chemotherapy. However, more effective therapy for poor-risk NB patients is still urgently needed.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Brain Neoplasms/therapy , Hematopoietic Stem Cell Transplantation , Neuroblastoma/therapy , Adult , Child, Preschool , Combined Modality Therapy , Female , Hematopoietic Stem Cell Mobilization , Humans , Infant , Male , Pilot Projects , Transplantation, Autologous , Treatment Outcome
9.
Bone Marrow Transplant ; 19(8): 765-9, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9134166

ABSTRACT

Umbilical cord blood stem cells (UCBSC) were used to reconstitute hematopoiesis following myeloablative therapy in a 13-month-old infant with acute nonlymphocytic leukemia (ANLL):FAB-M5 who had failed to sustain a chemotherapeutic remission. The patient's mother was 18 weeks pregnant with her second child at the time of diagnosis. Amniocentesis revealed that the fetus was HLA-haploidentical with the patient at the paternally inherited allele. The umbilical cord blood was harvested and processed by Ficoll centrifugation with 100% recovery of 5 x 10(7) mononuclear cells/kg and then cryopreserved. Two weeks after collection the cells were thawed and then infused into the patient following conditioning with total body irradiation, cyclophosphamide, and etoposide. Graft-versus-host-disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate. The patient experienced clinical grade I GVHD consisting of skin involvement only that resolved within 2 weeks following the addition of corticosteroids. Engraftment was achieved with an absolute neutrophil count (ANC) above 0.5 x 10(9)/l on day 16, a platelet count above 50 x 10(9)/l on day 56, platelet transfusion independence on day 32 and red blood cell transfusion independence after day 44. Three months following transplantation restriction fragment length polymorphism (RFLP) revealed no discernible difference between the donor and the recipient. The patient remains in remission without evidence of GVHD 23 months post-transplant.


Subject(s)
Fetal Blood/cytology , Hematopoietic Stem Cell Transplantation , Leukemia, Monocytic, Acute/therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Combined Modality Therapy , Female , Fetal Blood/immunology , Graft Survival , Graft vs Host Disease/etiology , Graft vs Host Disease/prevention & control , Haplotypes , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Infant , Infant, Newborn , Leukemia, Monocytic, Acute/drug therapy , Leukemia, Monocytic, Acute/immunology , Living Donors , Male , Polymorphism, Restriction Fragment Length , Pregnancy
SELECTION OF CITATIONS
SEARCH DETAIL